Pre-Diagnosis FEV1 Decline Predicts Mortality in Lung Transplant Recipients

Long-term survival following lung transplantation remains significantly lower than that of other solid organ transplants, primarily due to the development of chronic lung allograft dysfunction [1]. This clinical entity serves as an umbrella term for various immune-mediated pathways that result in progressive, often irreversible, graft injury [2, 3]. While current maintenance strategies frequently utilize tacrolimus (a calcineurin inhibitor used to suppress T-cell mediated rejection) to reduce the risk of chronic dysfunction, these interventions do not always translate into improved long-term survival [4]. Despite the use of anti-inflammatory agents like azithromycin to stabilize lung function in established cases, the clinical trajectory of the disease remains highly variable and difficult to forecast at the bedside [5, 6]. A new study now offers a method to risk-stratify these patients by analyzing the physiological history of the graft leading up to the clinical diagnosis, providing a clearer window into the expected course of decline.